SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Coloplast A/S (CLPBY) trades at a trailing P/E of 4.5, forward P/E of 2.6. Trailing earnings yield is 22.47%, forward earnings yield 38.46%. PEG 0.04 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (4.5); PEG ≤ 1.0 — Peter Lynch undervalued (0.04); analyst target implies upside (+113.8%); earnings yield beats bond yields (22.47%).
- Forward P/E 2.6 (down from trailing 4.5) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.04 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 22.47% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 38.46% as earnings recover.
- Analyst consensus target $14.45 (+113.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 72/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CLPBY
Valuation Multiples
P/E (TTM)4.5
Forward P/E2.6
PEG Ratio0.04
Forward PEG0.04
P/B Ratio0.00
P/S Ratio0.58
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.52
Forward EPS (Est.)$2.60
Book Value / Share$0.00
Revenue / Share$11.65
FCF / Share$0.00
Yields & Fair Value
Earnings Yield22.47%
Forward Earnings Yield38.46%
Dividend Yield0.00%
Analyst Target$14.45 (+113.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.48 |
$14.68B |
$3.14B |
21.4% |
| 2017 |
$1.79 |
$15.53B |
$3.8B |
24.5% |
| 2018 |
$1.81 |
$16.45B |
$3.85B |
23.4% |
| 2019 |
$1.82 |
$17.94B |
$3.87B |
21.6% |
| 2020 |
$1.97 |
$18.54B |
$4.2B |
22.6% |
| 2021 |
$2.26 |
$19.43B |
$4.83B |
24.8% |
| 2022 |
$2.21 |
$22.58B |
$4.71B |
20.8% |
| 2023 |
$2.22 |
$24.5B |
$4.78B |
19.5% |
| 2024 |
$2.25 |
$27.03B |
$5.05B |
18.7% |
| 2025 |
$1.52 |
$26.25B |
$3.43B |
13% |
